Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Jun;67(6):1351–1355. doi: 10.1038/bjc.1993.250

Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. IV: Pharmacokinetics and toxicity of flavone acetic acid and its metabolites.

M R Stratford 1, G J Rustin 1, M F Dennis 1, R R Watfa 1, N Howells 1, S M O'Reilly 1
PMCID: PMC1968479  PMID: 8512820

Abstract

Flavone acetic acid (FAA) was administered at a dose of 4.8 g m-2 over 1 h to patients with advanced malignant disease in combination with Interleukin II. A new high performance liquid chromatography method is described to determine both the parent compound and eight drug-related products, and the conditions required to determine these components in plasma are discussed. The half-life over the first 8 h was 2.3 h, but the terminal clearance of the drug was extremely slow. Severe (WHO Grade 4) hypotension was observed in some patients. However, incidence of this did not appear to be associated with any differences in FAA plasma concentrations, nor were there differences in FAA clearance between those patients whose tumour responded to the drug combination and those who did not.

Full text

PDF
1351

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bibby M. C., Double J. A., Phillips R. M., Loadman P. M. Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br J Cancer. 1987 Feb;55(2):159–163. doi: 10.1038/bjc.1987.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chabot G. G., Bissery M. C., Corbett T. H., Rutkowski K., Baker L. H. Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice. Cancer Chemother Pharmacol. 1989;24(1):15–22. doi: 10.1007/BF00254099. [DOI] [PubMed] [Google Scholar]
  3. Chabot G. G., Gouyette A. Reactivity of flavone acetic acid and its acyl glucuronide. Biochem Pharmacol. 1991 Aug 8;42(5):1145–1148. doi: 10.1016/0006-2952(91)90301-k. [DOI] [PubMed] [Google Scholar]
  4. Cummings J., Double J. A., Bibby M. C., Farmer P., Evans S., Kerr D. J., Kaye S. B., Smyth J. F. Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cancer Res. 1989 Jul 1;49(13):3587–3593. [PubMed] [Google Scholar]
  5. Cummings J., Kerr D. J., Kaye S. B., Smyth J. F. Optimisation of a reversed-phase high-performance liquid chromatographic method for the determination of flavone acetic acid and its major human metabolites in plasma and urine. J Chromatogr. 1988 Sep 23;431(1):77–85. doi: 10.1016/s0378-4347(00)83071-6. [DOI] [PubMed] [Google Scholar]
  6. Damia G., Freschi A., Sorio R., Braida A., Caruso G., Quaia M., Monfardini S., D'Incalci M. Flavone acetic acid distribution in human malignant tumors. Cancer Chemother Pharmacol. 1990;26(1):67–70. doi: 10.1007/BF02940298. [DOI] [PubMed] [Google Scholar]
  7. Haworth C., O'Reilly S. M., Chu E., Rustin G. J., Feldmann M. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies. Br J Cancer. 1993 Jun;67(6):1346–1350. doi: 10.1038/bjc.1993.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kerr D. J., Kaye S. B., Cassidy J., Bradley C., Rankin E. M., Adams L., Setanoians A., Young T., Forrest G., Soukop M. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res. 1987 Dec 15;47(24 Pt 1):6776–6781. [PubMed] [Google Scholar]
  9. O'Reilly S. M., Rustin G. J., Farmer K., Burke M., Hill S., Denekamp J. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma: I. Clinical and vascular studies. Br J Cancer. 1993 Jun;67(6):1342–1345. doi: 10.1038/bjc.1993.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Plowman J., Narayanan V. L., Dykes D., Szarvasi E., Briet P., Yoder O. C., Paull K. D. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep. 1986 May;70(5):631–635. [PubMed] [Google Scholar]
  11. Thomsen L. L., Baguley B. C., Rustin G. J., O'Reilly S. M. Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production. Br J Cancer. 1992 Oct;66(4):723–727. doi: 10.1038/bjc.1992.346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Wiltrout R. H., Boyd M. R., Back T. C., Salup R. R., Arthur J. A., Hornung R. L. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J Immunol. 1988 May 1;140(9):3261–3265. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES